XSHG
600055
Market cap1.09bUSD
Oct 09, Last price
10.48CNY
1D
0.96%
1Q
-3.59%
Jan 2017
-19.03%
Name
Beijing Wandong Medical Technology Co Ltd
Chart & performance
P/E
—
P/S
5.50
EPS
—
Div yield, %
1.25%
Shrs. gr., 5y
5.54%
Rev. gr., 5y
3.43%
Revenues
1.34b
-12.12%
Net income
-228m
L
CFO
-252m
L
Dividend
May 16, 20250.13 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Beijing Wandong Medical Technology Co., Ltd. focuses on the development, production, and sale of advanced medical diagnostic equipment. Their product lineup includes sophisticated MRI solutions, as well as a broad spectrum of radiological imaging systems. This range of radiological offerings features CT scanners, the CGO series, DR and DRF systems, digital mammography units, and mobile X-ray machines. The company, which was previously named China Resources Wandong Medical Equipment Co., Ltd., was founded in 1955 and maintains its headquarters in Beijing, China.
Key people
Chairman of the Board · since 2026
Jinsong Song
President, Director · since 2024
Xiaoquan Jing
Finance Director, Vice President · since 2018
Jiaxiang Huang
Vice President · since 2021
Yunbin Ou
Secretary of the Board · since 2024
Xiao Liu
Director · since 2021
Chibing Ma
Chairman of the Board · since 2025
Director · since 2021
Yan Sun
Independent Director · since 2024
Zhongkai Wu
Independent Director · since 2024
Jun Zhao
Independent Director · since 2024
Headquarters & legal address
北京市朝阳区酒仙桥东路9号院3号楼
朝阳区, BJ 100000
CN
朝阳区, BJ 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||